Rvx000222 (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
19 | ライソゾーム病 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03228940 (ClinicalTrials.gov) | September 30, 2019 | 18/7/2017 | Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease | An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease | Fabry Disease | Drug: RVX000222 | Resverlogix Corp | NULL | Not yet recruiting | 18 Years | 75 Years | All | 16 | Phase 1;Phase 2 | Canada |